Trial · NCT01928771
Adverse events330
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 330
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Benralizumab 30 mg q.4 Weeks | 8 | 403 | 12 |
| other | Nausea | Gastrointestinal disorders | Benralizumab 30 mg q.8 Weeks | 12 | 394 | 14 |
| other | Nausea | Gastrointestinal disorders | Placebo | 8 | 407 | 9 |
| other | Pyrexia | General disorders | Benralizumab 30 mg q.4 Weeks | 16 | 403 | 21 |
| other | Pyrexia | General disorders | Benralizumab 30 mg q.8 Weeks | 12 | 394 | 19 |
| other | Pyrexia | General disorders | Placebo | 8 | 407 | 8 |
| other | Acute sinusitis | Infections and infestations | Benralizumab 30 mg q.4 Weeks | 10 | 403 | 11 |
| other | Acute sinusitis | Infections and infestations | Benralizumab 30 mg q.8 Weeks | 13 | 394 | 14 |
| other | Acute sinusitis | Infections and infestations | Placebo | 11 | 407 | 15 |
| other | Bronchitis | Infections and infestations | Benralizumab 30 mg q.4 Weeks | 27 | 403 | 28 |
| other | Bronchitis | Infections and infestations | Benralizumab 30 mg q.8 Weeks | 19 | 394 | 22 |
| other | Bronchitis | Infections and infestations | Placebo | 30 | 407 | 41 |
| other | Gastroenteritis | Infections and infestations | Benralizumab 30 mg q.4 Weeks | 10 | 403 | 16 |
| other | Gastroenteritis | Infections and infestations | Benralizumab 30 mg q.8 Weeks | 12 | 394 | 14 |
| other | Gastroenteritis | Infections and infestations | Placebo | 6 | 407 | 6 |
| other | Influenza | Infections and infestations | Benralizumab 30 mg q.4 Weeks | 15 | 403 | 19 |
| other | Influenza | Infections and infestations | Benralizumab 30 mg q.8 Weeks | 19 | 394 | 21 |
| other | Influenza | Infections and infestations | Placebo | 23 | 407 | 31 |
| other | Nasopharyngitis | Infections and infestations | Benralizumab 30 mg q.4 Weeks | 47 | 403 | 62 |
| other | Nasopharyngitis | Infections and infestations | Benralizumab 30 mg q.8 Weeks | 47 | 394 | 69 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01928771/events